hca-i

Fluorometholone Acetate (Oxylone acetate) is a synthetic corticosteroid, used in the treatment of steroid responsive inflammatory conditions of the eye.

hCA I-IN-4 (Compound 14) is an inhibitor of carbonic anhydrase and cholinesterase, effectively inhibiting hCA I, hCA II, AChE, and BChE with Ki values of 29.94 nM, 17.72 nM, 21.21 nM, and 7.65 nM, respectively. It also demonstrates cytotoxicity in BT-549 cells, with an IC50 of 16.59 μM.

AChE hCA I-IN-1 (Compound L3) is an inhibitor of acetylcholinesterase (AChE) and carbonic anhydrase (CA), effectively inhibiting AChE, hCA I, and hCA II with IC50 values of 302 nM, 265 nM, and 283 nM, respectively.

hCA I-IN-3 (compound 24) is an aryl ether derivative that acts as a potent inhibitor of carbonic anhydrase. It effectively inhibits the hCA I and hCA II isoenzymes, with IC50 values of 4.77 and 9.66 nM, respectively. hCA I-IN-3 is potentially useful for research in oncology.

AChE/hCA I/II-IN-1 (Compound 6) is a potent AChE/Hca inhibitor with IC50 values of 22.21, 60.79, and 66.64 nM for AChE, Hca Ⅰ, and Hca Ⅱ. AChE/hCA I/II-IN-1 can be used in glaucoma, Alzheimer's disease, and diabetes research[1].

hCA I-IN-1 is a human carbonic anhydrase I (hCA I) inhibitor that acts on hCA I (Ki: 38.3 nM), hCA II (Ki: 716.4 nM), hCAIX (Ki: 940.1 nM) and hCAXII (Ki: 192.8 nM).

hCA I-IN-2 (Compound 6d) is a selective inhibitor of human carbonic anhydrase I (hCA I) with inhibition constants (Ki) as follows: 18.8 nM for hCA I, 375.1 nM for hCA II, 1721 nM for hCAIX, and 283.9 nM for hCAXII.

Histone acetyltransferase p300 Inhibitor 4c is a 2-aminothiazole derivative. Histone acetyltransferase p300 Inhibitor 4c inhibited hCA I, hCA II, AChE and BChE with Ki values of 0.008 ± 0.001, 0.124 ± 0.017, 0.129 ± 0.030 and 0.083 ± 0.041 µM. 0.017, 0.129 ± 0.030 and 0.083 ± 0.041 μM.

Methazolamide (CL 8490) is a carbonic anhydrase inhibitor that is used as a diuretic and in the treatment of glaucoma.

hCAIX-IN-5 was a selective hCAIX inhibitor, inhibiting hCAI, hCAII, hCAIV, and hCAIX with Ki values of >10000, >10000, 130.7, and 829.1 nM, respectively.

Carbonic anhydrase inhibitor 6 is a potent human carbonic anhydrase (hCA) inhibitor that inhibits hCA IX, hCA II, hCA XII, and hCA I. It is used in the study of diseases caused by abnormalities in carbonic anhydrase.

hCAIX XII-IN-13 functions as an inhibitor targeting specific human carbonic anhydrases (hCA) IX and XII, crucial in tumor-related processes. Demonstrating efficacy, this compound offers inhibitory K i values of 0.08 µM for IX and 0.06 µM for XII. Additionally, under hypoxic conditions, hCAIX XII-IN-13 enhances the effectiveness of Doxorubicin on MCF-7 cells by promoting G2 M phase cell cycle arrest and increasing apoptosis.

hBChE-IN-4 (compound 40) serves as an effective activator for hCA and an inhibitor for BChE. It demonstrates affinity for various hCA subtypes with affinity constants (KA) of 266 nM for hCA I, 76.9 nM for hCA II, 918 nM for hCA IV, 893 nM for hCA VB, and 98.0 nM for hCA VII. Inhibition concentrations (IC50) for eeAChE and eqBChE are recorded at 72.1 nM and 4.2 nM, respectively. hBChE-IN-4 is non-cytotoxic and has demonstrated potential cognitive enhancement effects. It holds potential for research in neurodegenerative and other neuropsychiatric disorders.

AChE CA I-IN-1 (Compound 2g) acts as an inhibitor for both AChE and hCA I, with Ki values of 1.85 µM and 0.53 µM, respectively. It has shown potential applications in the research of Alzheimer's disease, glaucoma, and epilepsy.

hCAI II-IN-10 (Compound 5d) is an inhibitor of human carbonic anhydrase I and II (hCA I and hCA II), with IC50 values of 4.32 nM and 3.89 nM, respectively.

Carbonic anhydrase inhibitor30 (compound 17) is an inhibitor of carbonic anhydrase with Ki values of 2.13 μM for hCA I and 0.161 μM for hCA II[1].

Carbonic anhydrase inhibitor32 (compound 5B) is an orally active, selective inhibitor of hCA (carbonic anhydrase) II/VII, with Ki values of 6.3 nM for hCA II, 10.1 nM for hCA VII, and 681 nM for hCA I. It shows potential for neuroprotection and anticonvulsant effects by reducing mTOR activation and increasing hippocampal KCC2 levels.

hCAIX/XII-IN-9 (compound 8) is a potent inhibitor of carbonic anhydrase (CA), with Ki values of 1658 nM for hCA I, 184.8 nM for hCA II, 8.9 nM for hCA IX, and 64.8 nM for hCA XII.

Carbonic anhydrase/AChE-IN-1 (compound 16) is an inhibitor of carbonic anhydrase and AChE, with Ki values of 24.42 nM for hCA I, 19.95 nM for hCA II, and 5.07 nM for AChE.

Carbonic anhydrase inhibitor20 (compound 11) is an inhibitor of piperazine-based sulfonamide carbonic anhydrase (Carbonic Anhydrase). It has Ki values of 47.6 nM, 36.5 nM, 8.3 nM, and 2.7 nM for hCA I, hCA II, hCA IX, and hCA XII, respectively.

hCAI/II-IN-8 (Compound 8) is a hydrazone derivative originating from 4-hydroxybenzaldehyde. It primarily inhibits human carbonic anhydrase isoenzymes I (hCA I) and II (hCA II) with IC50 values of 21.35 ± 0.39 nM for hCA I and 7.12 ± 0.12 nM for hCA II. It also exhibits inhibitory effects on AChE and BChE, with IC50 values of 46.27 ± 0.75 nM and 43.38 ± 0.83 nM, respectively.

Antibacterialagent 215 (Compound 3b) acts as an inhibitor of carbonic anhydrase (CA), with Ki values of 17.61, 5.14, and 43.74 nM for hCA I, hCA II, and AChE, respectively. It exhibits antitubercular activity with an MIC of 62.5 µg/ml against M. tuberculosis, and demonstrates antifungal potency against Candida spp. strains ATCC 14053, ATCC 1369, and ATCC 15126, with an MIC of 125 µg/ml.

Compound 6a, also known as Carbonic anhydrase inhibitor25, is an effective inhibitor of carbonic anhydrase enzymes, particularly hCA I and hCA II.

Carbonic anhydrase inhibitor23 (compound 40) is a potent inhibitor of carbonic anhydrase (CA), with Ki values of 617.2 nM for hCA I (α) and 434.1 nM for hCA II (α).